Definitions

1. FV Leiden mutation is a risk factor for VTE before and at time of diagnosis and for VTE recurrences.
2. Factor V Leiden mutation is present in up to 5% of the normal population and is the most common cause of familial thromboembolism.
3. Factor V Leiden mutation is a risk factor for cerebral venous thrombosis: a case-control study of 55 patients.
4. Factor V Leiden mutation (G1691A) (FVL) is the most common risk factor in venous thrombosis.
5. Factor V Leiden mutation is a risk factor for the development of thromboembolic events in pregnancy.

Mutation Accounts

1. Since this mutation accounts for 90% to 95% of APCR, a small percentage of patients will harbor APCR in the absence of a factor V Leiden mutation.

Heterozygous Factor

1. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia.

Women

1. Factor V Leiden mutation (G1691A) in women with recurrent spontaneous abortions from North India.

Rare Cases

1. In rare cases, both a null allele and factor V Leiden mutation occur on the same chromosome in cis configuration.

Deficiency

1. Examples of genetic tendencies include Protein C deficiency, Protein S deficiency, and the Factor V Leiden mutation.
2. In one patient with primary biliary cirrhosis factor V Leiden mutation and protein C deficiency were present simultaneously.

Factor Viii

1. The effect of the factor V Leiden mutation, high levels of fibrinogen, and increasing levels of factor VIII was stronger in males than in females.

Individuals

1. Individuals with the factor V Leiden mutation have inherited thrombophilia.

Mutations

1. The combination of the factor V Leiden mutation and mutations in other genes involved in blood clotting can also influence risk.

Risk

1. The risk of fetal loss in family members of probands with factor V Leiden mutation.
2. Neither the Factor V Leiden mutation nor MTHFR gene polymorphism increased the risk of thrombosis following hip replacement.

Transplantation

1. This retrospective study examined the effect of the factor V Leiden mutation on the risk of hepatic vessel thrombosis after liver transplantation.
2. We report on a patient with Budd-Chiari syndrome secondary to factor V Leiden mutation, who underwent successful liver transplantation.
3. Liver transplantation for acute Budd-Chiari syndrome in identical twin sisters with Factor V leiden mutation.

Fulminant Hepatic Failure

1. Acute Budd-Chiari syndrome with fulminant hepatic failure in a pregnant woman with factor V Leiden mutation.

Carriers

1. Increased risk for fetal loss in carriers of the factor V Leiden mutation.

Prevalence

1. The prevalence of the factor V Leiden mutation was determined in both cases and controls, and an odds ratio was calculated.
2. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis.

Activated

1. Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation.
2. Resistance to activated protein C and FV Leiden mutation in patients with a history of acute myocardial infarction or primary hypertension.

Factor Va

1. The factor V Leiden mutation affects one of the sites where APC cleaves the factor Va protein, slowing the rate at which factor V is inactivated.

Allele

1. Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation.

Heterozygous

1. The child and her father were both heterozygous for factor V Leiden mutation.

Patients

1. No donors or patients were homozygous for the factor V Leiden mutation.
2. Resistance to activated protein C and the leiden mutation: high prevalence in patients with abruptio placentae.
3. Budd-Chiari syndrome associated with factor V Leiden mutation: A report of 6 patients.

Cerebral Venous Thrombosis

1. Increased rate of factor V Leiden mutation in patients with cerebral venous thrombosis.

Venous Thromboembolism

1. Additional genetic risk factors for venous thromboembolism in carriers of the factor V Leiden mutation.
2. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation.

Factor

1. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.
2. Patients and controls with activated protein C resistance were further studied using a polymerase chain reaction assay for factor V Leiden mutation.
3. The risk of venous thromboembolism due to cancer outweighs the contribution of the factor V Leiden mutation.

Leiden Mutation

1. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis.
2. The odds ratio for having the factor V Leiden mutation in patients with venous thromboembolism was 0.3 (95% confidence interval 0.1, 1.7).
3. Other factors also increase the risk of blood clots in people with the factor V Leiden mutation.

Categories

1. Factor
2. Cerebral Venous Thrombosis
3. Venous Thromboembolism
4. Heterozygous
5. Society > Security > Risk > Odds Ratio
6. Books about "Leiden Mutation" in Amazon.com
   

Continue: More Keywords - - - - - - - - - -